BACKGROUND: Cardiac magnetic resonance techniques permit quantification of the myocardial extracellular volume fraction (ECV), representing a surrogate marker of reactive interstitial fibrosis, and late gadolinium enhancement (LGE), representing replacement fibrosis or scar. ECV and LGE have been independently linked with heart failure (HF) events. In deriving ECV, coronary artery disease type LGE, but not non-coronary artery disease type LGE, has been consistently excluded. We examined the associations between LGE, global ECV derived from myocardial tissue segments free of any detectable scar, and subsequent HF events. METHODS: Mid short-axis T1 maps were divided into 6 cardiac segments, each classified as LGE absent or present. Global ECV was derived from only segments without LGE. ECV was considered elevated if >30%, the upper 95% bounds of a reference group without known cardiac disease (n=28). Patients were divided into 4 groups by presence of elevated ECV and of any LGE. Subsequent HF hospitalization and any death were ascertained. Their relationship with ECV was examined separately and as a composite with Cox proportional hazard models. RESULTS: Of 1604 serial patients with T1 maps, 1255 were eligible after exclusions and followed over a median 26.3 (interquartile range, 15.9-37.5) months. Patients with elevated ECV had increased risk for death (hazard ratio [HR] 2.45 [95% CI, 1.76-3.41]), HF hospitalization (HR, 2.45 [95% CI, 1.77-3.40]), and a combined end point of both outcomes (HR, 2.46 [95% CI, 1.94-3.14]). After adjustments for covariates including LGE, the relationship persisted for death (HR, 1.82 [95% CI, 1.28-2.59]), hospitalization (HR, 1.60 [95% CI, 1.12-2.27]), and combined end points (HR, 1.73 [95% CI, 1.34-2.24]). CONCLUSIONS: ECV measures of diffuse myocardial fibrosis were associated with HF outcomes, despite exclusion of replacement fibrosis segments from their derivation and even among patients without any scar. ECV may have a synergistic role with LGE in HF risk assessment.
BACKGROUND: Cardiac magnetic resonance techniques permit quantification of the myocardial extracellular volume fraction (ECV), representing a surrogate marker of reactive interstitial fibrosis, and late gadolinium enhancement (LGE), representing replacement fibrosis or scar. ECV and LGE have been independently linked with heart failure (HF) events. In deriving ECV, coronary artery disease type LGE, but not non-coronary artery disease type LGE, has been consistently excluded. We examined the associations between LGE, global ECV derived from myocardial tissue segments free of any detectable scar, and subsequent HF events. METHODS: Mid short-axis T1 maps were divided into 6 cardiac segments, each classified as LGE absent or present. Global ECV was derived from only segments without LGE. ECV was considered elevated if >30%, the upper 95% bounds of a reference group without known cardiac disease (n=28). Patients were divided into 4 groups by presence of elevated ECV and of any LGE. Subsequent HF hospitalization and any death were ascertained. Their relationship with ECV was examined separately and as a composite with Cox proportional hazard models. RESULTS: Of 1604 serial patients with T1 maps, 1255 were eligible after exclusions and followed over a median 26.3 (interquartile range, 15.9-37.5) months. Patients with elevated ECV had increased risk for death (hazard ratio [HR] 2.45 [95% CI, 1.76-3.41]), HF hospitalization (HR, 2.45 [95% CI, 1.77-3.40]), and a combined end point of both outcomes (HR, 2.46 [95% CI, 1.94-3.14]). After adjustments for covariates including LGE, the relationship persisted for death (HR, 1.82 [95% CI, 1.28-2.59]), hospitalization (HR, 1.60 [95% CI, 1.12-2.27]), and combined end points (HR, 1.73 [95% CI, 1.34-2.24]). CONCLUSIONS: ECV measures of diffuse myocardial fibrosis were associated with HF outcomes, despite exclusion of replacement fibrosis segments from their derivation and even among patients without any scar. ECV may have a synergistic role with LGE in HF risk assessment.
Authors: Daniel R Messroghli; Sven Plein; David M Higgins; Kevin Walters; Timothy R Jones; John P Ridgway; Mohan U Sivananthan Journal: Radiology Date: 2006-01-19 Impact factor: 11.105
Authors: R J Kim; D S Fieno; T B Parrish; K Harris; E L Chen; O Simonetti; J Bundy; J P Finn; F J Klocke; R M Judd Journal: Circulation Date: 1999-11-09 Impact factor: 29.690
Authors: Andreas A Kammerlander; Beatrice A Marzluf; Caroline Zotter-Tufaro; Stefan Aschauer; Franz Duca; Alina Bachmann; Klaus Knechtelsdorfer; Matthias Wiesinger; Stefan Pfaffenberger; Andreas Greiser; Irene M Lang; Diana Bonderman; Julia Mascherbauer Journal: JACC Cardiovasc Imaging Date: 2015-12-09
Authors: Mark A Hlatky; Philip Greenland; Donna K Arnett; Christie M Ballantyne; Michael H Criqui; Mitchell S V Elkind; Alan S Go; Frank E Harrell; Yuling Hong; Barbara V Howard; Virginia J Howard; Priscilla Y Hsue; Christopher M Kramer; Joseph P McConnell; Sharon-Lise T Normand; Christopher J O'Donnell; Sidney C Smith; Peter W F Wilson Journal: Circulation Date: 2009-04-13 Impact factor: 29.690
Authors: Timothy C Wong; Kayla M Piehler; Ian A Kang; Ajay Kadakkal; Peter Kellman; David S Schwartzman; Suresh R Mulukutla; Marc A Simon; Sanjeev G Shroff; Lewis H Kuller; Erik B Schelbert Journal: Eur Heart J Date: 2013-06-11 Impact factor: 29.983
Authors: Daniel R Messroghli; James C Moon; Vanessa M Ferreira; Lars Grosse-Wortmann; Taigang He; Peter Kellman; Julia Mascherbauer; Reza Nezafat; Michael Salerno; Erik B Schelbert; Andrew J Taylor; Richard Thompson; Martin Ugander; Ruud B van Heeswijk; Matthias G Friedrich Journal: J Cardiovasc Magn Reson Date: 2017-10-09 Impact factor: 5.364
Authors: Erik B Schelbert; Yaron Fridman; Timothy C Wong; Hussein Abu Daya; Kayla M Piehler; Ajay Kadakkal; Christopher A Miller; Martin Ugander; Maren Maanja; Peter Kellman; Dipan J Shah; Kaleab Z Abebe; Marc A Simon; Giovanni Quarta; Michele Senni; Javed Butler; Javier Diez; Margaret M Redfield; Mihai Gheorghiade Journal: JAMA Cardiol Date: 2017-09-01 Impact factor: 14.676
Authors: Christopher A Miller; Josephine H Naish; Paul Bishop; Glyn Coutts; David Clark; Sha Zhao; Simon G Ray; Nizar Yonan; Simon G Williams; Andrew S Flett; James C Moon; Andreas Greiser; Geoffrey J M Parker; Matthias Schmitt Journal: Circ Cardiovasc Imaging Date: 2013-04-03 Impact factor: 7.792
Authors: Julian C Bachmann; Simon J Baumgart; Anna K Uryga; Markus H Bosteen; Giulia Borghetti; Michael Nyberg; Kate M Herum Journal: Cells Date: 2022-05-17 Impact factor: 7.666
Authors: Mateus D Marques; Raquel Weinberg; Shrey Kapoor; Mohammad R Ostovaneh; Yoko Kato; Chia Ying Liu; Steven Shea; Robyn L McClelland; Wendy S Post; David A Bluemke; João A C Lima; Bharath Ambale-Venkatesh Journal: Eur Heart J Cardiovasc Imaging Date: 2022-09-10 Impact factor: 9.130
Authors: Mohammad A Khan; Eric Y Yang; Duc T Nguyen; Faisal Nabi; Jeremy Hinojosa; Maria Jabel; Sherif F Nagueh; Edward A Graviss; Dipan J Shah Journal: Circ Cardiovasc Imaging Date: 2020-07-15 Impact factor: 7.792
Authors: Scott R Shuldiner; Lye-Yeng Wong; Tess E Peterson; Julian Wolfson; S Jermy; H Saad; Mbalabu A J Lumbamba; A Singh; M Shey; G Meintjes; N Ntusi; M Ntsekhe; J V Baker Journal: Open Forum Infect Dis Date: 2020-12-07 Impact factor: 3.835
Authors: Katherine C Wu; Sabina A Haberlen; Michael W Plankey; Frank J Palella; Damani A Piggott; Gregory D Kirk; Joseph B Margolick; Wendy S Post Journal: Eur Heart J Cardiovasc Imaging Date: 2021-07-20 Impact factor: 6.875